Dr. Mary Jo Fidler on the Role of Oligoclonal T Cell Expansion in NSCLC
October 26th 2016
Mary Jo Fidler, MD, associate professor, medical oncology, hematology, internal medicine, Rush University Medical Center, discusses how early and persistent oligoclonal T cell expansion correlates with durable response to anti-PD1 therapy in non-small cell lung cancer treatment (NSCLC).